Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- SCYX
- Price
- 0.76
- Stock movement up
- +0.01 (1.36%)
- Company name
- Scynexis Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 28.05M
- Ent value
- 27.89M
- Price/Sales
- 3.27
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -49.32%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2025-12-04
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
SCYX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.27 |
| Price to Book | - |
| EV to Sales | 3.26 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 41.92M |
| EPS (TTM) | -0.51 |
| FCF per share (TTM) | -0.67 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 2.93M |
| Gross profit (TTM) | 2.93M |
| Operating income (TTM) | -34.63M |
| Net income (TTM) | -25.30M |
| EPS (TTM) | -0.51 |
| EPS (1y forward) | -0.06 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | -1181.07% |
| Profit margin (TTM) | -862.89% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 14.88M |
| Net receivables | 10.00M |
| Total current assets | 48.69M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 1.85M |
| Total assets | 51.07M |
| Accounts payable | 3.47M |
| Short/Current long term debt | 2.28M |
| Total current liabilities | 8.47M |
| Total liabilities | 14.64M |
| Shareholder's equity | 36.43M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -33.59M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -33.59M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -69.45% |
| Return on Assets | -49.54% |
| Return on Invested Capital | -68.58% |
| Cash Return on Invested Capital | -91.05% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.65 |
| Daily high | 0.67 |
| Daily low | 0.65 |
| Daily Volume | 154K |
| All-time high | 145.00 |
| 1y analyst estimate | 3.67 |
| Beta | 1.36 |
| EPS (TTM) | -0.51 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 1 Apr 2026 |
Downside potential
Loading...
Downside potential data
| SCYX | S&P500 | |
| Current price drop from All-time high | -99.48% | -0.89% |
| Highest price drop | -99.60% | -19.00% |
| Date of highest drop | 17 Nov 2025 | 8 Apr 2025 |
| Avg drop from high | -99.33% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 290 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
28.05M
Marketcap category
Small-cap
Description
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Employees
28
Website
Investor relations
-
SEC filings
CEO
Marco Taglietti
Country
USA
City
Jersey City
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page